-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, French scientists published a review article in the journal Nature Reviews Clinical Oncology to introduce the current progress and direction of oncolytic therapies other than oncolytic viruses (Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies | Nature Reviews Clinical Oncology).
Drug source analysis
Drug source analysisOncolytic virus is already a clinically proven concept, and T-Vec is listed.
Physical and chemical oncolysis therapy does not have this obstacle, but oncolysis is a concept that is still relatively vaguely defined, so how to develop such drugs is still at an exploratory stage.
Theoretically, there are two advantages of oncolytic drugs.
The systemic toxicity of chemotherapy is a big problem, basically the child and the bath water are thrown out together.
Immunotherapy is the biggest breakthrough in tumor treatment in the past 10 years, and oncolytic drugs are the next frontier of immunotherapy, and are expected to become general-purpose tumor treatment drugs.